Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kite Pharma

Kite Pharma
2009 FOUNDED
M&A STATUS
501-600 EMPLOYEES
M&A LATEST DEAL TYPE
$12B LATEST DEAL AMOUNT
Description

Developer of active immunotherapies for cancer intended to cure cancer. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. It's dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
  • 2400 Broadway
  • Santa Monica, CA 90404
  • United States

+1 (310) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kite Pharma’s full profile, request a free trial.

Kite Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 03-Oct-2017 $12B 00000 0000 Completed Profitable
4. Secondary Transaction - Open Market 01-Apr-2015 00000 Completed Generating Revenue
3. IPO 20-Jun-2014 00000 00000 00000 Completed Generating Revenue
2. Mezzanine 28-Apr-2014 $50M $85M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 15-May-2013 $35M $35M 00000 Completed Clinical Trials - Phase 2
To view this company’s complete deal history including valuation and funding, request access »

Kite Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Kite Pharma Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Venture Capital-Backed Philadelphia, PA 0000 00000000000 0000
000000000 Formerly VC-backed Vancouver, Canada 000 00000 00000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Kite Pharma Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 28-Aug-2019 00000 00000 00 0000 Drug Discovery
000000 19-Jul-2018 000000000 00000000 Biotechnology
0000000 (000,000 0 12-Apr-2018 000000000 00000 00 00000 Buildings and Property 000000 000 00.0
00000 0000 0000000 01-Apr-2017 00000 0000000 Drug Discovery 0000 0000000000 00
Cell Design Labs 16-Jun-2016 Later Stage VC 000 Biotechnology 0000 0000000000 00
To view this company’s complete investment and acquisition history, request access »

Kite Pharma Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alta Partners Venture Capital Minority 000 0000 000000 0
Arie Belldegrun Angel (individual) Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
Commercial Street Capital Other Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Kite Pharma Executive Team (19)

Name Title Board
Seat
Contact
Info
Prentice Curry Senior Vice President, Quality and Compliance
Adrian Bot Ph.D Vice President, Scietific Officer
Christi Shaw Chief Executive Officer & Board Member

16 Former Executives

You’re viewing 3 of 19 executives. Get the full list »

Kite Pharma Board Members (9)

Name Representing Role Since Contact
Info
Christi Shaw Self Chief Executive Officer & Board Member 000 0000
Roy Doumani Kite Pharma Independent Director 000 0000

7 Former Board Members

You’re viewing 2 of 9 board members. Get the full list »